LIXTE Biotechnology Holdings has expanded its collaboration with The University of Texas MD Anderson Cancer Center and pharmaceutical manufacturer GSK on an ongoing clinical trial evaluating its proprietary compound LB-100 in combination with GSK's Dostarlimab for ovarian clear cell cancer treatment. The trial, initiated in January 2024 and led by Amir Jazaeri, MD, at MD Anderson, has added a second site at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University under Emily M. Hinchcliff, MD, MPH, and is expected to double enrollment to 42 patients following completion of its initial 21-patient target.
This expansion represents a significant step in addressing ovarian clear cell cancer, a particularly aggressive form of ovarian cancer that has historically shown limited response to conventional treatments. The trial's growth from one to two major cancer research centers increases both patient access and scientific validation, potentially accelerating the development timeline for this novel combination therapy. Data from the initial cohort is expected to be presented in the first half of 2026, providing crucial insights into the treatment's efficacy and safety profile.
LIXTE's lead compound, LB-100, represents a pioneering approach in cancer biology known as activation lethality, which advances a new treatment paradigm for cancer therapy. The company has demonstrated that LB-100 is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data available at https://www.lixte.com, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for cancer patients.
The importance of this trial expansion lies in its potential to address an unmet medical need for ovarian clear cell cancer patients who have limited treatment options. The collaboration between a biotechnology company, a leading academic cancer center, and a major pharmaceutical manufacturer represents a model for accelerating cancer drug development. If successful, this combination therapy could establish a new standard of care for this challenging cancer subtype and potentially extend to other cancer types.
Additional information about LIXTE can be found at https://lixte.com/. The company's comprehensive patent portfolio covers this new approach to cancer treatment, with proof-of-concept clinical trials currently in progress for both Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The expansion of this trial reflects growing confidence in the therapeutic approach and represents a critical milestone in bringing potentially transformative treatments to patients with limited options.
